- Home
- ADTX vs DRMA Comparison
ADTX vs DRMA Comparison
Compare ADTX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTX
- DRMA
- Stock Information
- Founded
- ADTX 2017
- DRMA 2014
- Country
- ADTX United States
- DRMA United States
- Employees
- ADTX N/A
- DRMA N/A
- Industry
- ADTX Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- ADTX Health Care
- DRMA Health Care
- Exchange
- ADTX Nasdaq
- DRMA Nasdaq
- Market Cap
- ADTX 5.3M
- DRMA 4.5M
- IPO Year
- ADTX 2020
- DRMA 2021
- Fundamental
- Price
- ADTX $1.66
- DRMA $0.79
- Analyst Decision
- ADTX
- DRMA Strong Buy
- Analyst Count
- ADTX 0
- DRMA 1
- Target Price
- ADTX N/A
- DRMA $6.00
- AVG Volume (30 Days)
- ADTX 215.2K
- DRMA 182.0K
- Earning Date
- ADTX 05-27-2025
- DRMA 05-14-2025
- Dividend Yield
- ADTX N/A
- DRMA N/A
- EPS Growth
- ADTX N/A
- DRMA N/A
- EPS
- ADTX N/A
- DRMA N/A
- Revenue
- ADTX $55,323.00
- DRMA N/A
- Revenue This Year
- ADTX $15,768.94
- DRMA N/A
- Revenue Next Year
- ADTX N/A
- DRMA N/A
- P/E Ratio
- ADTX N/A
- DRMA N/A
- Revenue Growth
- ADTX N/A
- DRMA N/A
- 52 Week Low
- ADTX $2.04
- DRMA $0.69
- 52 Week High
- ADTX $27,200.00
- DRMA $6.17
- Technical
- Relative Strength Index (RSI)
- ADTX 29.72
- DRMA 42.98
- Support Level
- ADTX $1.57
- DRMA $0.75
- Resistance Level
- ADTX $1.85
- DRMA $0.99
- Average True Range (ATR)
- ADTX 0.22
- DRMA 0.07
- MACD
- ADTX 0.28
- DRMA 0.01
- Stochastic Oscillator
- ADTX 12.00
- DRMA 23.46
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.